Fernando C Fervenza MD

Glomerular Disease

Consultant Nephrologist

200 1st St SWRochester, MN 55905
Phone+1 507-284-2511
Fax+1 507-266-7891

Dr. Fervenza is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Fervenza's full profile Already have an account?

Summary

Dr. Fernando Fervenza is a nephrologist based in Rochester, MN, with a subspecialty in glomerular disease. He completed his medical education at the Pontificia University Catolica do Rio Grande do Sul, Brazil, followed by nephrology and research training at the University of Oxford, England, and subsequent fellowship and residency training at Stanford and Mayo Clinic, respectively. Dr. Fervenza has been serving as the Section Head of Parenchymal Renal Disease and a Professor of Medicine at the Mayo Clinic, where he has been a consultant nephrologist since 1999. His research and clinical interests are in glomerular diseases. He has authored publications in renowned journals such as The New England Journal of Medicine and Kidney International has contributed to multiple clinical trials focusing on diseases like membranous nephropathy. Dr. Fervenza has received several certifications for CMS Meaningful Use from GE Healthcare and the Mayo Clinic.

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1997 - 1999
Stanford Health Care-Sponsored Stanford UniversityFellowship, Nephrology, 1993 - 1997
University of OxfordPh.D., 1991
Federal University of Rio Grande do Sul School of MedicineClass of 1982

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MN State Medical License 1998 - 2026
AL State Medical License 1996 - 2001
American Board of Internal Medicine Nephrology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Centricity Enterprise (CE), GE Healthcare, 2014-2015, 2017
CMS Meaningful Use Stage 1 Certification Centricity Patient Online, GE Healthcare, 2014-2015, 2017
CMS Meaningful Use Stage 2 Certification Centricity Patient Online, GE Healthcare, 2014-2015, 2017

Clinical Trials

Rituximab in the Treatment of Idiopathic Membranous Nephropathy
COMPLETED
EARLY_PHASE1
CellCept in p-ANCA Vasculitis
COMPLETED
PHASE1
Rituxan in Churg Strauss Syndrome With Renal Involvement
TERMINATED
PHASE2

Publications & Presentations

PubMed

Response to the Letter to the Editor Entitled "Critical Reappraisal of Obinutuzumab Randomized Trials in Membranous Nephropathy".
Kajaree Giri, Richard J Glassock, Fernando C Fervenza
Kidney International Reports. 2026-09-01
Evaluating sparsentan for the treatment of focal segmental glomerulosclerosis.
Cristián Juanet, María José Soler, Ladan Zand, Fernando C Fervenza
Expert Opinion on Pharmacotherapy. 2026-08-24
A multi-center cohort study evaluated hemoglobinuria as a marker of inflammation in IgA nephropathy.
Maria J Vargas-Brochero, Anila Cara, Andrea Angioi, Nicola Lepori, Roberta Fenoglio
Kidney International. 2026-08-21

Journal Articles

CKD Due to a Novel Mitochondrial DNA Mutation: A Case Report
Fernando C Fervenza, Karl A Nath, American Journal of Kidney Diseases
Congophilic Fibrillary Glomerulonephritis: A Case Series
Stephen B Erickson, Fernando C Fervenza, Nelson Leung, American Journal of Kidney Diseases
The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study
Musab S Hommos, Fernando C Fervenza, Mariam P Alexander, Mayo Clinic Proceedings

Books/Book Chapters

Core concepts in parenchymal kidney disease
Chapter: Preface
Fervenza FC, Lin J, Sethi S, Singh AKEditors: Fervenza FC; et al.Springer, New York, NY2014
Core concepts in parenchymal kidney disease
Chapter: Membranous nephropathy.
Page 51 - 75Fervenza FC, Passerini P, Sethi S, Ponticelli CEditors: Fervenza FC; et al.Springer, New York, NY2014
Core concepts in parenchymal kidney disease.
Chapter: Preface.
Fervenza FC, Lin J, Sethi S, Singh AKEditors: Fervenza FC; et al.Springer, New York, NY2014

Abstracts/Posters

"Urinary Soluble Urokinase Receptor (suPAR) is Not Elevated in Membranous Nephropathy (MN) and Does Not Correlate with Proteinuria"
F.C. Fervenza, ASN, Philadelphia, 1/1/2014
"C3 Glomerulonephritis Associated With Autoimmune Disorders: A Case Series".
F.C. Fervenza, ASN, Philadelphia, 1/1/2014
"Impact of weight loss before renal transplantation in obese patients: risk of early mortality.
F.C. Fervenza, ASN, Philadelphia, 1/1/2014

Lectures

"B-cell depletion in nephrotic syndrome"
San Francisco, CA - 7/18/2014
"Clinical presentation and treatment considerations in complement-mediated glomerular diseases"
National University of Ireland, Galway - 6/14/2014
"Membranous Nephropathy New Insights Regarding Diagnosis And Treatment"
University of Iowa, Iowa City - 6/4/2014

Other

The Authors Reply
Fernando Fervenza, MD, Kidney International
https://www.doximity.com/articles/0d06e5eb-70ad-4a29-8688-037c2b736df2
UpToDate, Wolters Kluwer Health - 2012-09-17
Emerging Indications for the use of Rituximab in Glomerular Disease.
Kattah AG, Fervenza FC, NephSAP Volume 11, Number 3
1/1/2012
Clinical presentation, classification, and causes of membranoproliferative glomerulonephritis
Fervenza FC, Sethi S
http://www.uptodate.com/contents/clinical-presentation-classification-and-causes-of-membranoprolifer
UpToDate, Wolters Kluwer Health - 2012-09-12

Authored Content

The Authors ReplyAugust 2018
Congophilic Fibrillary Glomerulonephritis: A Case SeriesJune 2018

Press Mentions

Practical Issues with Implementation of New C3G TherapiesAugust 13th, 2025
Two Kidney Disease Therapies Square off in MENTOR TrialAugust 20th, 2019
Rituximab Tops Cyclosporine in Membranous NephropathyJuly 3rd, 2019

Grant Support

Membranous Nephropathy Observational Cohort StudyNational Institute Of Diabetes And Digestive And Kidney Diseases2009–2011
Pulse Dexamethasone Over 48 Weeks For Podocyte DiseasesNational Center For Research Resources2005
Pulse Dexamethasone In Focal Segmental GlomerulosclerosisNational Center For Research Resources2004–2005